Tovorafenib | m-entrepreneurship.com

Product Name :
Tovorafenib

Search keywords :
Tovorafenib

drugId :
null

Target Vo:
Serine/threonine-protein kinase B-raf

Target Vo Short Name :
B-raf

Moa_Name:
Serine/threonine-protein kinase B-raf inhibitors

First Approval Country :
United States

First Approval Date Filter:
2024

Origin Company_Name :
Sunesis Pharmaceuticals Inc

Active Company_Name :
Day One Biopharmaceuticals Inc

Active Indication_Name:
Glioma

In Active Indication_Name:
Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
EIF2A Rabbit mAb Technical Information
JAK2 Rabbit mAb Technical Information
ATP Citrate Lyase Antibody (YA829): ATP Citrate Lyase Antibody (YA829) is a non-conjugated and Mouse origined monoclonal antibody about 121 kDa, targeting to ATP Citrate Lyase (3D9). It can be used for WB,ICC/IF,FC assays with tag free, in the background of Human, Mouse, Monkey.

Author: Betaine hydrochloride

Related Posts